MIAMI, Nov. 11, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it has rescheduled its third quarter 2026 financial results conference call and webcast to 4:30 p.m. Eastern Time, after the close of U.S. financial markets on Thursday, November 12, 2026, from its previously announced time of 8:30 a.m. Eastern Time.
The revised timing will allow management to provide investors with a more comprehensive update on the Company’s recent developments and business activities in conjunction with its third quarter financial results.
Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live audio webcast and an archive of the recording will be available here and through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the start of the call.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Investor Contact:
Jeff Warren
LifeSci Advisors
jwarren@lifesciadvisors.com
investor-relations@inspiremd.com


Đề xuất
Global Times: China helps weave a greener Asia-Pacific by turning its development gains into shared opportunities
JOYY Reports Third Quarter 2026 Unaudited Financial Results
Seventy Years of Diplomatic Ties, Masks as a New Language: Colorful Guizhou Launches China–Egypt Dialogue of Civilizations Through Theatrical Masks
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
REEcycle Holdings, Inc. and Hall Chadwick Acquisition Corp. Announce Additional $15.0 Million PIPE Commitments from Leading Institutional Stockholders